The company views patents and monopolies as necessary ingredients for success, while others suggest the strategy hinders industry growth and innovation.
The past year saw plummeting valuations for psychedelic companies, a late comeback for stock values, emerging methodical challenges in clinical trials, and some organizations’ strategic – but contested – move away from psychedelia’s “cultural baggage.”
In this interview, Firefly VR founder Shel Mann discusses how immersive technology can help prepare patients for psychedelic therapies, and the integration of virtual tools into mainstream healthcare.
The early results of a COMPASS Pathways clinical trial quell some concerns related to the safety of psychedelic therapy for individuals with bipolar disorder.
**Contribute to the Future of Psychedelics** Make an investment in a healthy psychedelic future by supporting this community-funded initiative. For the last 3 years, Lucid News has been providing indispensable journalism covering the psychedelic field. We are now turning to our readers to continue building. We understand that not everyone is in a position to pay for this vital information, but if you are, we need you. *Make an investment in quality journalism, so others can benefit. You can give just once or monthly. Thank you.*
**Contribute to the Future of Psychedelics** Make an investment in a healthy psychedelic future by supporting this community-funded initiative. For the last 3 years, Lucid News has been providing indispensable journalism covering the psychedelic field. We are now turning to our readers to continue building. We understand that not everyone is in a position to pay for this vital information, but if you are, we need you. *Make an investment in quality journalism, so others can benefit. You can give just once or monthly. Thank you.*